On the other hand, amplification of MDM2 and EGFR mutations is related to hyperprogression among patients with advanced solid cancers during ICB treatment,12 and PD‐1 blockade could trigger immune escape in lung cancers driven by EGFR, as shown in preclinical studies.138. This evidence concerns the gene EGFR and lung carcinoma.